Less than 10% of individuals that would benefit from obesity jabs including Wegovy can access them, states the World Health Organization as it publishes its first guidance on the medications.
With in excess of 1,000,000,000 individuals worldwide now obese, it is urging increased and just access to GLP-1 medication.
According to projections, more than two billion could be living with obesity by 2030 without intervention.
"Our new guidance recognises that excess weight is a chronic disease that can be managed with comprehensive and continuous treatment," remarked the agency's head Tedros Adhanom Ghebreyesus.
High costs, insufficient output, and supply-chain constraints are major barriers to broad access to the jabs that can aid individuals in losing substantial weight, explains the organization.
Skinny Jab Shortage
Even in the present best projected outlook, the supply of these medications might only reach around 100 million people – under 10% of eligible patients, as stated by the health organization.
The recommendation encourages nations and manufacturers to expand availability, via strategies such as voluntary licensing.
A patent on semaglutide – the core component of Novo Nordisk's Wegovy – is set to lapse in a number of countries in 2026.
The Way Weight-Loss Injections Operate
GLP-1 drugs imitate a biological compound to delay gastric emptying, reduce hunger and increase feelings of fullness so individuals reduce food intake.
Patients usually see weight reduction after several weeks of beginning the weekly injections.
Evidence suggests patients may regain a significant portion within a year of stopping the treatment, as their usual hunger resume.
To be above a healthy weight increases your chance for contracting health problems, including type 2 diabetes, heart disease, stroke, and specific malignancies.
Excess weight concerns people in countries worldwide and was responsible for 3.7 million fatalities worldwide in 2024, according to the health agency.
